Prospective Randomized Open Blinded End-point (PROBE) Study. A Novel Design for Intervention Trials. Prospective Randomized Open Blinded End-Point

Overview

Journal Blood Press

Specialty Cardiology & Vascular Diseases

Date 1992 Aug 1

PMID 1366259

Citations 157

Authors

L Hansson

T Hedner

B Dahlof

Affiliations

Soon will be listed here.

Abstract

A novel design for intervention studies is presented, the so called PROBE study (Prospective Randomized Open, Blinded End-point). This design is compared to the classical double-blind design. Among the advantages of the PROBE design are lower cost and greater similarity to standard clinical practice, which should make the results more easily applicable in routine medical care. Since end-points are evaluated by a blinded end-point committee it is obvious that there should be no difference between the two types of trials in this regard.

Citing Articles

Impact of central adjudication of the score on the modified Rankin Scale in an international, randomized, acute stroke trial.

Sluis W, de Jonge J, Reinink H, Wilson A, Woodhouse L, Dawson J Eur Stroke J. 2025; :23969873251320207.

PMID: 39968909 PMC: 11840822. DOI: 10.1177/23969873251320207.

Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT.

Onida S, Tan M, Balan V, Heatley F, Peerbux S, Bolton-Saghdaoui L Br J Surg. 2025; 112(2).

PMID: 39960153 PMC: 11831364. DOI: 10.1093/bjs/znae330.

Upstream targeting for the prevention of atrial fibrillation: Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)-rationale and study design.

Wass S, Barnard J, Kim H, Sun H, Telfer W, Schilling T J Interv Card Electrophysiol. 2024; 68(1):9-19.

PMID: 39671157 PMC: 11832320. DOI: 10.1007/s10840-024-01955-z.

Protocol for the Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Studies.

Faustino E, Kandil S, Leroue M, Sochet A, Kong M, Cholette J Pediatr Crit Care Med. 2024; 26(1):e95-e105.

PMID: 39560771 PMC: 11717624. DOI: 10.1097/PCC.0000000000003648.

Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.

Hobbs F, McManus R, Taylor C, Jones N, Rahman J, Wolstenholme J Nat Med. 2024; 30(12):3634-3645.

PMID: 39349629 PMC: 11753262. DOI: 10.1038/s41591-024-03263-5.